Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study

Morgenstern DA, Pötschger U, Moreno L, Papadakis V, Owens C, Ash S, Pasqualini C, Luksch R, Garaventa A, Canete A, Elliot M, Wieczorek A, Laureys G, Kogner P, Malis J, Ruud E, Beck-Popovic M, Schleiermacher G, Valteau-Couanet D, Ladenstein R.

Pediatr Blood Cancer. 2018 Nov;65(11):e27363. doi: 10.1002/pbc.27363. Epub 2018 Jul 17. PMID: 30015396.

Previous
Previous

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with HR-NBL (HR-NBL1/SIOPEN ph 3 trial)

Next
Next

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Ph 2 Trial